A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects-Reference-Cited by-同舟云学术

A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects

Published:2020 Issue:19 Volume:12 Page:10799-10808
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Hu Jin¹²³⁴⁵^ORCID,Wang Min⁶³⁴⁵⁷^ORCID,Xiao Xinyue⁶³⁴⁵⁷,Zhang Bo¹²³⁴⁵,Xie Qiu¹²³⁴⁵,Xu Xinjie¹²³⁴⁵,Li Shengjie¹²³⁴⁵,Zheng Zhifa¹²³⁴⁵,Wei Daixu⁸⁹¹⁰¹¹¹²^ORCID,Zhang Xuan⁶³⁴⁵⁷^ORCID

Affiliation:

1. Department of Medical Research Center

2. Peking Union Medical College Hospital

3. Chinese Academy of Medical Sciences and Peking Union Medical College

4. Beijing 100730

5. China

6. Clinical Immunology Center& Epigenetics Center

7. Department of Rheumatology and Clinical Immunology

8. Key Laboratory of Resource Biology and Biotechnology in Western China

9. Ministry of Education

10. School of Medicine

11. Department of Life Sciences and Medicine

12. Northwest University

Abstract

A polyhydroxyalkanoate terpolymer based drug delivery platform loaded with immunosuppressant for systemic lupus erythematosus therapy with less systemic toxicity.

Funder

National Natural Science Foundation of China

Chinese Academy of Medical Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2020/NR/D0NR01308K

Reference35 articles.

1. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

2. Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus